ORR stratified by cohort and by baseline characteristics
| . | n . | ORR % (95% CI) . |
|---|---|---|
| Carfilzomib cohort | ||
| Overall (N = 126) | 47.6 (38.7-56.7) | |
| Cohort 1 (20 mg/m2 only) | 59 | 42.4 (29.6-55.9) |
| Cohort 2 (20/27 mg/m2) | 67 | 52.2 (39.7-64.6) |
| Baseline characteristics | ||
| Age, y | ||
| < 65 | 58 | 58.6 (44.9-71.4) |
| ≥ 65 | 68 | 38.2 (26.7-50.8) |
| ECOG performance status | ||
| 0 | 51 | 52.9 (38.5-67.1) |
| ≥ 1 | 75 | 44.0 (32.5-55.9) |
| ISS stage | ||
| I | 52 | 57.7 (43.2-71.3) |
| II | 41 | 34.1 (20.1-50.6) |
| III | 20 | 45.0 (23.1-68.5) |
| Baseline neuropathy | ||
| Grade 0 | 59 | 39.0 (26.5-52.6) |
| ≥ grade 1 | 66 | 56.1 (43.3-68.3) |
| Cytogenetic/FISH prognostic markers | ||
| Normal/favorable | 100 | 51.0 (40.8-61.1) |
| Poor | 19 | 36.8 (16.3-61.6) |
| Serum β2-microglobulin, mg/L | ||
| < 5.5 | 93 | 47.3 (36.9-57.9) |
| ≥ 5.5 | 20 | 45.0 (23.1-68.5) |
| Received prior lenalidomide | ||
| Yes | 74 | 41.9 (30.5-53.9) |
| No | 52 | 55.8 (41.3-69.5) |
| Received prior thalidomide | ||
| Yes | 75 | 56.0 (44.1-67.5) |
| No | 51 | 35.3 (22.4-49.9) |
| . | n . | ORR % (95% CI) . |
|---|---|---|
| Carfilzomib cohort | ||
| Overall (N = 126) | 47.6 (38.7-56.7) | |
| Cohort 1 (20 mg/m2 only) | 59 | 42.4 (29.6-55.9) |
| Cohort 2 (20/27 mg/m2) | 67 | 52.2 (39.7-64.6) |
| Baseline characteristics | ||
| Age, y | ||
| < 65 | 58 | 58.6 (44.9-71.4) |
| ≥ 65 | 68 | 38.2 (26.7-50.8) |
| ECOG performance status | ||
| 0 | 51 | 52.9 (38.5-67.1) |
| ≥ 1 | 75 | 44.0 (32.5-55.9) |
| ISS stage | ||
| I | 52 | 57.7 (43.2-71.3) |
| II | 41 | 34.1 (20.1-50.6) |
| III | 20 | 45.0 (23.1-68.5) |
| Baseline neuropathy | ||
| Grade 0 | 59 | 39.0 (26.5-52.6) |
| ≥ grade 1 | 66 | 56.1 (43.3-68.3) |
| Cytogenetic/FISH prognostic markers | ||
| Normal/favorable | 100 | 51.0 (40.8-61.1) |
| Poor | 19 | 36.8 (16.3-61.6) |
| Serum β2-microglobulin, mg/L | ||
| < 5.5 | 93 | 47.3 (36.9-57.9) |
| ≥ 5.5 | 20 | 45.0 (23.1-68.5) |
| Received prior lenalidomide | ||
| Yes | 74 | 41.9 (30.5-53.9) |
| No | 52 | 55.8 (41.3-69.5) |
| Received prior thalidomide | ||
| Yes | 75 | 56.0 (44.1-67.5) |
| No | 51 | 35.3 (22.4-49.9) |
The table is based on a response-evaluable population.